Metabolic & Cardiometabolic
SGLT1 inhibition increases GLP-1 secretion
📅 Last reviewed: 2026-08-11 ⓘ
Evidence ladder
How far up the ladder this claim has climbed. A high consensus on a low rung means "consistent so far," not "proven in people."
Top evidence so far: Human trials (RCT / n-of-1)
How the studies fall
What the evidence shows
The premise behind shunting glucose distally to trigger L-cells — and the human evidence is genuinely split, which matters because a whole formulation strategy rests on it. The Lexicon LX4211 trials report increased total GLP-1 and PYY. But a Copenhagen crossover in RYGB patients found SGLT1/2 inhibition did not raise 4-hour GLP-1 iAUC (p=0.
The evidence (4)
| Source | Grade | Stance | Quality | Finding |
|---|---|---|---|---|
| Zambrowicz B, et al. 2013 · Clinical therapeutics | RCT | supports | moderate | Dose-timing study, n=12 healthy: LX4211 increased total GLP-1 and PYY alongside reduced postprandial glucose, consistent with unabsorbed glucose reaching distal L-cells. |
| Martinussen C, et al. 2020 · American journal of physiology. Endocrinology and metabolism | RCT | contradicts | high | Primary outcome NULL and partly reversed: canagliflozin did NOT reduce 4-h GLP-1 iAUC (6,067 vs 7,273, p=0.23) but LOWERED peak GLP-1 by 28% (p=0.03) and cut GIP iAUC 28%. Authors conclude SGLT1-mediated glucose absorption CONTRIBUTES to incretin secretion. Randomized controlled crossover, n=10 post-RYGB. Directly opposes the shunt-to-boost-GLP-1 premise in this population. |
| Zambrowicz B, et al. 2013 · Clinical therapeutics | RCT | supports | moderate | LX4211 significantly increased total GLP-1 and total PYY and reduced total GIP in T2DM patients; combination with sitagliptin significantly increased ACTIVE GLP-1 vs either monotherapy. n=18, open-label 3-way crossover. |
| Io F, et al. 2019 · European journal of pharmacology | animal | supports | moderate | SGL5213 enhanced plasma total GLP-1 and GLP-2 in rats and delivered unabsorbed glucose to caecum/colon at 3-9h, supporting the distal-delivery mechanism. Rat; timing of the GLP-1 rise is delayed relative to a meal. |
Disagree, or know a study we missed?
We grade by evidence, not opinions. The way to weigh in is to point us to a study we haven't cited (check the evidence table above first), or to flag a problem with one we have. Every submission is reviewed; if it holds up, the grade updates and shows in Science Changes Its Mind.
Opens a short form. You'll sign in with Google so submissions are tied to a real account — we don't display your identity, and we only accept a link we can verify (PubMed, DOI, ClinicalTrials.gov).
Educational only, not medical advice. Grades and scores reflect published evidence weighted by study design and quality; see the methodology.